Despite the clinical benefit of Trastuzumab combined with chemotherapy in improving the overall survival of HER2-positive advanced GC (AGC), the disease progressed in most patients within one year because of acquired Trastuzumab resistance [4, 5]. This evidence concerns the gene ERBB2 and gastric cancer.